Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Receivables: 2020-2022

  • Mereo BioPharma Group's Receivables fell 5.34% to $2.4 million in Q2 2022 from the same period last year, while for Jun 2022 it was $10.4 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2021, which is 28.51% up from last year.
  • As of Q2 2022, Mereo BioPharma Group's Receivables stood at $2.4 million, which was down 19.91% from $3.0 million recorded in Q4 2021.
  • In the past 5 years, Mereo BioPharma Group's Receivables ranged from a high of $3.0 million in Q4 2021 and a low of $1.6 million during Q2 2020.
  • Moreover, its 3-year median value for Receivables was $2.4 million (2022), whereas its average is $2.4 million.
  • In the last 5 years, Mereo BioPharma Group's Receivables soared by 59.51% in 2021 and then decreased by 5.34% in 2022.
  • Mereo BioPharma Group's Receivables (Quarterly) stood at $2.4 million in 2020, then grew by 24.97% to $3.0 million in 2021, then dropped by 5.34% to $2.4 million in 2022.
  • Its last three reported values are $2.4 million in Q2 2022, $3.0 million for Q4 2021, and $2.5 million during Q2 2021.